Is APGE or ATRA more undervalued in 2026?

CirclFi compares Apogee Therapeutics, Inc. (APGE) and Atara Biotherapeutics, Inc. (ATRA) using 13 institutional-grade valuation models. APGE has a Quality of Company score of 4.2/10 while ATRA scores 4.8/10.

Which is a better buy — APGE or ATRA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do APGE and ATRA valuations compare?

APGE at $82.14 and ATRA at $10.51 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

APGE vs ATRA Valuation Comparison 2026 — Intrinsic Value Analysis

APGE

Biological Products, (No Diagnostic Substances)

Apogee Therapeutics, Inc.

Quality

4.2

out of 10

Value Trap

SAFE

Price

$82.14

Last close

Models

10/13

Active

ATRA

Biological Products, (No Diagnostic Substances)

Atara Biotherapeutics, Inc.

Quality

4.8

out of 10

Value Trap

SAFE

Price

$10.51

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	APGE Fair Value	APGE Upside	ATRA Fair Value	ATRA Upside
Bayesian DCF	Intrinsic	$27.78	-66.2%	$1.88	-82.2%
Earnings Power Value	Intrinsic	$37.75	-55.9%	$49.72	+496.1%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for APGE vs ATRA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

APGE vs ATRA — Which Stock Is More Undervalued?

ATRA scores higher with a 4.8/10 quality rating vs APGE's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Apogee Therapeutics, Inc. (APGE) and Atara Biotherapeutics, Inc. (ATRA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

APGE currently trades at $82.14 with a QOC of 4.2/10, while ATRA trades at $10.51 with a QOC of 4.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).